Narrative updates are currently in beta.

Back to narrative

Update shared on29 Jul 2025

Fair value Increased 24%
AnalystConsensusTarget's Fair Value
€135.24
14.8% overvalued intrinsic discount
06 Aug
€155.20
Loading
1Y
205.5%
7D
6.3%

The significant upward revision in AlzChem Group’s price target is underpinned by improved consensus forecasts for both revenue growth and net profit margin, resulting in a new fair value estimate of €124.40.


What's in the News


  • AlzChem Group AG confirmed 2025 earnings guidance, expecting sales to reach approximately EUR 580 million.
  • Sales are projected to be higher in the second half of the year, driven by increased demand in custom manufacturing and positive trends in the NITRALZ product area.

Valuation Changes


Summary of Valuation Changes for AlzChem Group

  • The Consensus Analyst Price Target has significantly risen from €100.71 to €124.40.
  • The Consensus Revenue Growth forecasts for AlzChem Group has significantly risen from 7.7% per annum to 9.2% per annum.
  • The Net Profit Margin for AlzChem Group has significantly risen from 11.56% to 12.83%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.